Document is current
Any future updates will be listed below
-
Authors
Schwarzmann, Laura
Stöhr, Robert
Emons, Julius
Pöschke, Patrik
Seitz, Katharina
Rübner, Matthias
Beckmann, Matthias W.
Diederich, Mareike Britt
Unser, Irina
Hartmann, Arndt
Matek, Christian
Erber, Ramona
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (No: 70116663)
Interdisciplinary Center for Clinical Research (IZKF) at the University Hospital of the University of Erlangen-Nuremberg (Junior Project J101)
Young Scientist Fellowship by the Bavarian Center for Cancer Research
- License Information
-
More Information
Article History
Received: 20 February 2026
Accepted: 15 May 2026
First Online: 6 June 2026
Competing interests
: R.E. has received honoraria from Roche, Eisai, Pfizer, BioNTech, Lilly, Veracyte (PROCURE), Diaceutics, Mindpeak, AstraZeneca, MEDAC, Menarini Stemline, MSD, and Novartis. The institution of A.H. and R.E. has received research funding or conducted contracted research for AstraZeneca, Roche, NanoString Technologies, Biocartis, ZytoVision, Novartis, Cepheid, Mindpeak, MSD, Gilead, palleos healthcare, QuIP, Owkin, and BioNTech. R.E. is Associate Editor of npj precision oncology. R.E. was not involved in the journal’s review of, or decisions related to, this manuscript. All other authors declare no financial or non-financial competing interests.
